Tiago Fauth
Stock Analyst at Wells Fargo
(2.10)
# 2,745
Out of 4,944 analysts
148
Total ratings
38.46%
Success rate
-5.71%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $24.68 | +25.61% | 3 | Aug 13, 2025 | |
| INSM Insmed | Maintains: Overweight | $130 → $140 | $125.69 | +11.39% | 7 | Aug 12, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $78 → $79 | $47.65 | +65.81% | 4 | Aug 8, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $432.70 | -8.71% | 7 | Aug 1, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $24 → $21 | $8.52 | +146.62% | 3 | Jul 31, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $314 → $295 | $306.78 | -3.84% | 6 | Jul 31, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $28.79 | +125.77% | 8 | Jul 10, 2025 | |
| VRNA Verona Pharma | Downgrades: Equal-Weight | $138 → $107 | $105.29 | +1.62% | 7 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $50.57 | +50.29% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $2.75 | +154.55% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $22.29 | +353.12% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.58 | +89.87% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $13.86 | +87.59% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $7.16 | +137.60% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.66 | +145.90% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $61.10 | +22.75% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $2.81 | +2,106.41% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $191.15 | -53.44% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $18.86 | +170.49% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $57.21 | +109.74% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $15.67 | -74.47% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $3.05 | +359.02% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $6.47 | +302.17% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $4.61 | +507.38% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $26.81 | +202.13% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.39 | +1,938.74% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.07 | +1,208.41% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $0.66 | +5,059.33% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $3.36 | +4,364.29% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $38.39 | -24.46% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $2.05 | +534.15% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $3.04 | +327.63% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $0.83 | +140.96% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $645.96 | -47.37% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $287.85 | -10.02% | 1 | Apr 28, 2021 |
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $24.68
Upside: +25.61%
Insmed
Aug 12, 2025
Maintains: Overweight
Price Target: $130 → $140
Current: $125.69
Upside: +11.39%
PTC Therapeutics
Aug 8, 2025
Maintains: Overweight
Price Target: $78 → $79
Current: $47.65
Upside: +65.81%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $432.70
Upside: -8.71%
Wave Life Sciences
Jul 31, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $8.52
Upside: +146.62%
United Therapeutics
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $314 → $295
Current: $306.78
Upside: -3.84%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $28.79
Upside: +125.77%
Verona Pharma
Jul 10, 2025
Downgrades: Equal-Weight
Price Target: $138 → $107
Current: $105.29
Upside: +1.62%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $50.57
Upside: +50.29%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $2.75
Upside: +154.55%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $22.29
Upside: +353.12%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.58
Upside: +89.87%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $13.86
Upside: +87.59%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $7.16
Upside: +137.60%
Dec 20, 2024
Initiates: Overweight
Price Target: $9
Current: $3.66
Upside: +145.90%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $61.10
Upside: +22.75%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $2.81
Upside: +2,106.41%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $191.15
Upside: -53.44%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $18.86
Upside: +170.49%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $57.21
Upside: +109.74%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $15.67
Upside: -74.47%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.05
Upside: +359.02%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $6.47
Upside: +302.17%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $4.61
Upside: +507.38%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $26.81
Upside: +202.13%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.39
Upside: +1,938.74%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.07
Upside: +1,208.41%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $0.66
Upside: +5,059.33%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $3.36
Upside: +4,364.29%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $38.39
Upside: -24.46%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $2.05
Upside: +534.15%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $3.04
Upside: +327.63%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $0.83
Upside: +140.96%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $645.96
Upside: -47.37%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $287.85
Upside: -10.02%